Fabio Guolo
IRCCS Policlinico San Martino, UO Clinica Ematologica - Genova
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fabio Guolo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06667973 · Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaGruppo Italiano Malattie EMatologiche dell'Adulto · not yet recruiting · Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:21 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 57 citationsRCR 2.5
- Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.Br J Haematol · 201430 citationsRCR 0.9
- Osteopathic Manipulative Treatment and Cardiovascular Autonomic Parameters in Rugby Players: A Randomized, Sham-Controlled Trial.J Manipulative Physiol Ther · 202112 citationsRCR 1.4
- Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.Am J Hematol · 20259 citationsRCR 2.2
- 5 citationsRCR 0.2
- Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.Blood Adv · 20254 citationsRCR 1.0